Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Sitagliptin
Sulfonylurea
Metformin
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Glucose metabolism disorders Metabolic diseases Peptidase inhibitors
Eligibility Criteria
Inclusion Criteria:
- Muslim, with type 2 diabetes mellitus
- Intends to fast during the month of Ramadan
- Hemoglobin A1c (HbA1c) ≤10% at screening
- On a stable dose of a SU drug (glibenclamide, glimepiride, or gliclazide), for at least three months, with or without metformin therapy at a stable dose
Exclusion Criteria:
- Type 1 diabetes mellitus
- Pregnant or breast feeding or with gestational diabetes
- Hypersensitivity or contraindication to dipeptidyl peptidase-4 (DPP-4) treatment
- Serum creatinine ≥1.5 mg/dL (males), ≥1.4 mg/dL (females)
- History of severe hypoglycemia (defined as a hypoglycemic event requiring the assistance of another individual, and/or resulting in a emergency department admission, physician office visit and/or hospitalization)
- Any use of insulin (prior to or during Ramadan)
- Use of any class of oral antidiabetic therapy other than an SU or metformin
- Current participation in another interventional study
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Sitagliptin
Sulfonylurea Therapy
Arm Description
Sitagliptin 100mg taken orally once daily with or without metformin
Usual sulfonylurea therapy with or without metformin
Outcomes
Primary Outcome Measures
Percentage of Participants With at Least One Symptomatic Hypoglycemic Event
Symptomatic hypoglycemic events were based on the participants own self-reported symptoms (for example, but not limited to the following: faintness, headache, confusion, anxiety, sweating, tremor, palpitations, nausea, pallor, dizziness, hunger, sudden behavioral change).
Secondary Outcome Measures
Percentage of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event
Symptomatic hypoglycemic events were based on the participants own self-reported symptoms (for example but not limited to the following: faintness, headache, confusion, anxiety, sweating, tremor, palpitations, nausea, pallor, dizziness, hunger, sudden behavioral change). Asymptomatic hypoglycemic events were based on self-monitored finger-stick blood glucose level.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01340768
Brief Title
Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)
Official Title
An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting
Study Type
Interventional
2. Study Status
Record Verification Date
May 2017
Overall Recruitment Status
Completed
Study Start Date
June 22, 2010 (Actual)
Primary Completion Date
September 21, 2011 (Actual)
Study Completion Date
September 21, 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a study comparing the incidence of hypoglycemia while using sitagliptin treatment versus sulfonylurea (SU) treatment in participants with type 2 diabetes mellitus (T2DM) who regularly take an SU drug, and choose to fast during the month of Ramadan. The primary hypothesis is that during the 30 days of Ramadan fasting, treatment with sitagliptin (with or without metformin) compared to SU treatment (with or without metformin) results in a lower incidence of hypoglycemia in participants with T2DM.
Detailed Description
This study and NCT01131182 (MK-0431-263) have the same design but are conducted under separate protocols, in different countries, according to local guidelines.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Glucose metabolism disorders Metabolic diseases Peptidase inhibitors
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
870 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sitagliptin
Arm Type
Experimental
Arm Description
Sitagliptin 100mg taken orally once daily with or without metformin
Arm Title
Sulfonylurea Therapy
Arm Type
Active Comparator
Arm Description
Usual sulfonylurea therapy with or without metformin
Intervention Type
Drug
Intervention Name(s)
Sitagliptin
Other Intervention Name(s)
Sitagliptin phosphate, MK-0431, JANUVIA®
Intervention Description
One 100 mg tablet taken orally once daily
Intervention Type
Drug
Intervention Name(s)
Sulfonylurea
Other Intervention Name(s)
Amaryl (glimepiride)
Intervention Description
Participant continued pre-study sulfonylurea therapy (dose as prescribed by the physician). Pre-study sulfonylurea therapy consisted of either glibenclamide, glimepiride or gliclazide.
Intervention Type
Drug
Intervention Name(s)
Metformin
Other Intervention Name(s)
Glucophage
Intervention Description
Participants receiving metformin at enrollment, continued pre-study doses of metformin. If necessary, the physician could either discontinue or adjust the dose of metformin during Ramadan.
Primary Outcome Measure Information:
Title
Percentage of Participants With at Least One Symptomatic Hypoglycemic Event
Description
Symptomatic hypoglycemic events were based on the participants own self-reported symptoms (for example, but not limited to the following: faintness, headache, confusion, anxiety, sweating, tremor, palpitations, nausea, pallor, dizziness, hunger, sudden behavioral change).
Time Frame
Up to 30 days (Day 1 through last day of Ramadan)
Secondary Outcome Measure Information:
Title
Percentage of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event
Description
Symptomatic hypoglycemic events were based on the participants own self-reported symptoms (for example but not limited to the following: faintness, headache, confusion, anxiety, sweating, tremor, palpitations, nausea, pallor, dizziness, hunger, sudden behavioral change). Asymptomatic hypoglycemic events were based on self-monitored finger-stick blood glucose level.
Time Frame
Up to 30 days (Day 1 through last day of Ramadan)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Muslim, with type 2 diabetes mellitus
Intends to fast during the month of Ramadan
Hemoglobin A1c (HbA1c) ≤10% at screening
On a stable dose of a SU drug (glibenclamide, glimepiride, or gliclazide), for at least three months, with or without metformin therapy at a stable dose
Exclusion Criteria:
Type 1 diabetes mellitus
Pregnant or breast feeding or with gestational diabetes
Hypersensitivity or contraindication to dipeptidyl peptidase-4 (DPP-4) treatment
Serum creatinine ≥1.5 mg/dL (males), ≥1.4 mg/dL (females)
History of severe hypoglycemia (defined as a hypoglycemic event requiring the assistance of another individual, and/or resulting in a emergency department admission, physician office visit and/or hospitalization)
Any use of insulin (prior to or during Ramadan)
Use of any class of oral antidiabetic therapy other than an SU or metformin
Current participation in another interventional study
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
Citations:
PubMed Identifier
22738801
Citation
Aravind SR, Ismail SB, Balamurugan R, Gupta JB, Wadhwa T, Loh SM, Suryawanshi S, Davies MJ, Girman CJ, Katzeff HL, Radican L, Engel SS, Wolthers T. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Curr Med Res Opin. 2012 Aug;28(8):1289-96. doi: 10.1185/03007995.2012.707119. Epub 2012 Jul 6.
Results Reference
derived
Learn more about this trial
Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)
We'll reach out to this number within 24 hrs